AzTrials
AzTrials

Acute Lymphoblastic LeukemiaEarly Phase 1NCT04227015

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

A Early Phase 1 study testing CTA101 in people with Acute Lymphoblastic Leukemia and Non-hodgkin Lymphoma, run by He Huang at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy Read more about this study

Who is it for?
Ages 3 to 70 years
What is being tested?
CTA101
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
72 participants
Where
1 siteChina
Study dates
8 Jan 2020to 31 May 2027
Phase
Early Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 3 to 70 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Male or female aged ≥ 3 and <70 years old;
  • Histologically confirmed diagnosis of CD19+ B-ALL per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphoblastic Leukemia (2016.v1);
  • Relapsed or refractory CD19+ B-ALL (meeting one of the following conditions):
  • CR not achieved after standardized chemotherapy;
  • CR achieved following the first induction, but CR duration is ≤ 12 months;
  • Ineffective after first or multiple remedial treatments;
Show all 24Show fewer
  • 2 or more recurrences;
  • The number of primordial cells (lymphoblast and prolymphocyte) in bone marrow is >5% (morphology) and/or >1% (Flow cytometry);
  • Philadelphia-chromosome-negative (Ph-) patients; or Philadelphia-chromosome-positive (Ph+) patients who cannot tolerate TKI treatments or do not respond to 2 TKI treatments;
  • Male or female aged ≥ 18 and <70 years old;
  • Histologically confirmed diagnosis per WHO Classification Criteria for Lymphocytic Tumors 2016, including DLBCL(NOS), follicular lymphoma, Chronic lymphoblastic leukemia/small lymphoblastic lymphoma transforms DLBCL, PMBCL and high grade B cell lymphoma;
  • Relapsed or refractory DLBCL (meeting one of the following conditions):
  • No remission or recurrence after receiving second-line or above second-line chemotherapy;
  • Primary drug resistance;
  • Recurrence after autologous hematopoietic stem cell transplantation
  • According to Lugano 2014, there should be at least one evaluable tumor lesion.
  • Applicable standards for ALL and NHL:
  • HLA antibody(-) or HLA antibody(+) and HLA donor specific antibody(DSA)(-);
  • total bilirubin ≤ 51umol/L, ALT and AST ≤ 3 times of upper limit of normal, creatinine ≤ 176.8umol/L;
  • Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%;
  • No active infection in the lungs, blood oxygen saturation by sucking air is ≥ 92%;
  • Estimated survival time ≥ 3 months;
  • ECOG performance status 0 to 2;
  • Patients or their legal guardians volunteer to participate in the study and sign the informed consent.

Who cannot join

  • patients with extramedullary lesions, except those with CNSL (CNS-1) under effective control (for ALL patients only);
  • Confirmed diagnosis of lymphoblastic crisis of chronic myeloid leukemia, Burkitt's leukemia/lymphoma per WHO Classification Criteria (for ALL patients only);
  • Patients with hereditary syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome (for ALL patients only);
  • patients with intracranial extralateral lesions (cerebrospinal fluid tumor cells and/or intracranial lymphoma invasion shown by MRI) (for NHL patients only) ;
  • extensive involvement of gastrointestinal lymphoma (for NHL patients only);
  • radiotherapy, chemotherapy and monoclonal antibody within 1 week before screening;
Show all 27Show fewer
  • Have a history of allergy to any of the components in the cell products;
  • Prior treatment with any CAR T cell product or other genetically-modified T cell therapies;
  • According to the New York heart association (NYHA) cardiac function classification criteria, Subjects with grade III or IV cardiac insufficiency;
  • Myocardial infarction, cardioangioplasty or stenting, unstable angina pectoris, or other severe cardiac diseases within 12 months of enrollment;
  • Severe primary or secondary hypertension of grade 3 or above (WHO Hypertension Guidelines, 1999);
  • Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
  • History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia, and cerebrovascular hemorrhagic diseases;
  • Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis).
  • Indwelling catheters in vivo (e.g. percutaneous nephrostomy, Foley catheter, bile duct catheter, or pleural/peritoneal/pericardial catheter). Ommaya storage, dedicated central venous access catheters such as Port-a-Cath or Hickman catheters are allowed;
  • History of other primary cancer, except for the following conditions:
  • Cured non-melanoma after resection, such as basal cell carcinoma of the skin;
  • Cervical cancer in situ, localized prostate cancer, ductal cancer in situ with disease-free survival ≥ 2 years after adequate treatment;
  • Patients with autoimmune diseases requiring treatment, patients with immunodeficiency or requiring immunosuppressive therapy;
  • Patients with graft-versus-host disease (GVHD);
  • Prior immunizations with live vaccine 4 weeks prior to screening;
  • History of alcoholism, drug abuse or mental illness;
  • If HBsAg positive at screening, HBV DNA copy number detected by PCR in patients with active hepatitis B > 1000 (if HBV DNA copy number≤1000, routine antiviral therapy is required after enrollment), as well as CMV, hepatitis C, syphilis infection;
  • Concurrent therapy with systemic steroids within 1 week prior to screening, except for the patients recently or currently receiving inhaled steroids;
  • Patients who have participated in any other clinical studies within 2 weeks prior to screening;
  • pregnant and breast-feeding women and the subjects who are fertile and unable to take effective contraceptive measures (regardless of the gender);
  • Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

China1 site, 1 recruiting

  • The First Hospital of Zhejiang Medical Colleage Zhejiang University

    Hangzhou, Zhejiang, 310003

    He Huang, MD, 86-13605714822, hehuangyuzj@163.com

    Jimin Shi, MD, 86-13857119907, jiminshi@126.com

    Recruiting

Other trials in China

About this study

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy

Read the detailed description

This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory CD19+ B-line hematological malignancy: B-ALL and B-NHL. the selection of dose levels and the number of subjects are based on clinical tiral of similar foreign products. 2 groups of patients will be enrolled, 36 in each group. Primary objective is to explore the safety, main consideration is dose-related safety.

Being tested
CTA101
Medical subject headings
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CTA101Drug

    Also called CTA101 UCAR-T cell injection

    CTA101 UCAR-T cell injection by intravenous infusion

Study groups in NCT04227015
Study groupRoleWhat they receive
Administration of CTA101ExperimentalDose escalation follows the standard 3+3 dose escalation design. A total of 2 dose levels are set for subjects.
Receives: Drug: CTA101

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Dose-limiting toxicity (DLT)

    Adverse events assessed according to NCI-CTCAE v5.0 criteria

    Measured: Baseline up to 28 days after CTA101 infusion

  2. Incidence of treatment-emergent adverse events (TEAEs)

    Incidence of treatment-emergent adverse events [Safety and Tolerability]

    Measured: Up to 2 years after CTA101 infusion

Secondary outcomes (6)

  1. B-cell acute lymphocytic leukemia (B-ALL), MRD negative overall response rate (MRD- ORR)

    Assessment of MRD negative overall response rate (MRD- ORR) at 3 months after CTA101 infusion

    Measured: 3 months

  2. B-ALL, Event-free survival (EFS)

    From the first infusion of CTA101 to the occurrence of any event, including death, relapse or gene relapse, disease progression (any one occurs first), and the last visit

    Measured: Month 6, 12, 18 and 24

  3. B-ALL, Overall response rate (ORR)

    Assessment of ORR (ORR = CR + CRi ) at Month 6, 12, 18 and 24

    Measured: Month 6, 12, 18 and 24

  4. B-ALL, Overall survival (OS)

    From the first infusion of CTA101 to death or the last visit

    Measured: Month 6, 12, 18 and 24

  5. B cell non-hodgkin's lymphoma (B-NHL), Overall response rate (ORR)

    Assessment of ORR (ORR = CR + PR ) per Lugano 2014 criteria

    Measured: weeks 4, 12, months 6, 12, 18 and 24

  6. B-NHL,disease control rate (DCR)

    Assessment of DCR (DCR=CR+PR+SD) per Lugano 2014 criteria

    Measured: weeks 12, months 6, 12, 18 and 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jan 2020
  2. Study start8 Jan 2020
  3. Primary completion8 Jan 2022 (estimated)
  4. Study completion31 May 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
72 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04227015
Sponsor's protocol ID
BHCT-CTA101-08
Status last verified
Dec 2020
First submitted
8 Jan 2020
Last updated
28 Dec 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing CTA101 in people with Acute Lymphoblastic Leukemia and Non-hodgkin Lymphoma, run by He Huang at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 24 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 28 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Dose-limiting toxicity (DLT) (time frame: Baseline up to 28 days after CTA101 infusion). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04227015.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Dec 2020.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in